Market diffusion of biosimilars in off-patent biologic drug markets across Europe
AK Böhm, IM Steiner, T Stargardt - Health Policy, 2023 - Elsevier
Biologics are among the most expensive pharmaceuticals but have begun to lose their
exclusivity rights over the past 15 years, offering the possibility for biosimilar competition …
exclusivity rights over the past 15 years, offering the possibility for biosimilar competition …
The risk-value trade-off: price and brand information impact consumers' intentions to purchase OTC drugs
L Aufegger, C Yanar, A Darzi… - Journal of pharmaceutical …, 2021 - Taylor & Francis
Background European countries face fiscal pressure regarding the long-term sustainability
of their healthcare system due to increasing levels of public health expenditures and …
of their healthcare system due to increasing levels of public health expenditures and …
Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical …
KB Son - Expert Review of Pharmacoeconomics & Outcomes …, 2022 - Taylor & Francis
Background The nature of competition within the pharmaceutical sector has received a great
deal of attention from policymakers and researchers. This is the first study to …
deal of attention from policymakers and researchers. This is the first study to …
Sacubitril/valsartan (LCZ696): a novel treatment for heart failure and its estimated cost effectiveness, budget impact, and disease burden reduction in Germany
A Gandjour, DA Ostwald - Pharmacoeconomics, 2018 - Springer
Background Heart failure affects over 1 million people in Germany and contributes to
morbidity, mortality, and high healthcare costs. A recent large randomized controlled trial …
morbidity, mortality, and high healthcare costs. A recent large randomized controlled trial …
Attitude and purchase intention to generic drugs
R Arcaro, CRP da Veiga, WV da Silva… - International Journal of …, 2021 - mdpi.com
Generic drugs were instituted in 1984 in the United States. Since that time, many studies
have been conducted in several countries into consumer attitude and behavior when …
have been conducted in several countries into consumer attitude and behavior when …
Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation
KE Blankart, S Vandoros - Plos one, 2024 - journals.plos.org
Background Healthcare systems worldwide face escalating pharmaceutical expenditures
despite interventions targeting pricing and generic substitution. Existing studies often …
despite interventions targeting pricing and generic substitution. Existing studies often …
Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between …
M Lottes, V Bremer, C Prugger, C Kollan… - BMC health services …, 2022 - Springer
Background Recent patent losses for antiretroviral drugs (ARV) have led to the debate of
cost-saving through the replacement of patented drugs with generic drugs. The split of …
cost-saving through the replacement of patented drugs with generic drugs. The split of …
Generic atorvastatin and rosuvastatin in the South Korean market: time of introduction in relation to manufacturer characteristics
KB Son - Expert Review of Pharmacoeconomics & Outcomes …, 2020 - Taylor & Francis
Background: The competition for and market dynamics of generic medicines can be
understood by analyzing manufacturers' behavior. In this study, we analyzed the various …
understood by analyzing manufacturers' behavior. In this study, we analyzed the various …
The same old medicine but cheaper: The impact of patent expiry on physicians' prescribing behaviour
We study the evolution of statin consumption between 2005-2017 in the Italian region Emilia-
Romagna. We run an interrupted time series analysis on monthly data for the three market …
Romagna. We run an interrupted time series analysis on monthly data for the three market …
The effects of dynamic and static competition on prescription drug prices in Denmark, 1997–2017
FR Lichtenberg - Journal of Evolutionary Economics, 2022 - Springer
A recent study examined the effects of both dynamic (between-substance) and static (within-
substance) competition on prescription drug prices in the US It showed that the 1985–2005 …
substance) competition on prescription drug prices in the US It showed that the 1985–2005 …